PI3K	B:C1450115
δ	I:C1450115
and	O
PI3K	O
γ	I:C2713509
isoforms	I:C2713509
have	O
distinct	O
functions	O
in	O
regulating	O
pro-tumoural	O
signalling	O
in	O
the	O
multiple	O
myeloma	I:C0026764
microenvironment	O
.	O

PI3K	O
δ	I:C1450115
and	O
PI3K	B:C2713509
γ	I:C2713509
isoforms	I:C2713509
have	O
distinct	O
functions	O
in	O
regulating	O
pro-tumoural	O
signalling	O
in	O
the	O
multiple	O
myeloma	I:C0026764
microenvironment	O
.	O

PI3K	O
δ	I:C1450115
and	O
PI3K	O
γ	I:C2713509
isoforms	I:C2713509
have	O
distinct	O
functions	O
in	O
regulating	O
pro-tumoural	B:C0027651
signalling	O
in	O
the	O
multiple	O
myeloma	I:C0026764
microenvironment	O
.	O

PI3K	O
δ	I:C1450115
and	O
PI3K	O
γ	I:C2713509
isoforms	I:C2713509
have	O
distinct	O
functions	O
in	O
regulating	O
pro-tumoural	O
signalling	B:C0037083
in	O
the	O
multiple	O
myeloma	I:C0026764
microenvironment	O
.	O

PI3K	O
δ	I:C1450115
and	O
PI3K	O
γ	I:C2713509
isoforms	I:C2713509
have	O
distinct	O
functions	O
in	O
regulating	O
pro-tumoural	O
signalling	O
in	O
the	O
multiple	B:C0026764
myeloma	I:C0026764
microenvironment	O
.	O

Phosphoinositide	B:C0044602
-	I:C0044602
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
and	O
protein	O
kinase	I:C0164786
B	I:C0164786
(	O
PI3K	O
-	O
AKT	O
)	O
is	O
upregulated	O
in	O
multiple	O
myeloma	I:C0026764
(	O
MM	I:C0026764
)	I:C0026764
.	O

Phosphoinositide	O
-	I:C0044602
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
and	O
protein	B:C0164786
kinase	I:C0164786
B	I:C0164786
(	O
PI3K	O
-	O
AKT	O
)	O
is	O
upregulated	O
in	O
multiple	O
myeloma	I:C0026764
(	O
MM	I:C0026764
)	I:C0026764
.	O

Phosphoinositide	O
-	I:C0044602
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
and	O
protein	O
kinase	I:C0164786
B	I:C0164786
(	O
PI3K	B:C0044602
-	O
AKT	O
)	O
is	O
upregulated	O
in	O
multiple	O
myeloma	I:C0026764
(	O
MM	I:C0026764
)	I:C0026764
.	O

Phosphoinositide	O
-	I:C0044602
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
and	O
protein	O
kinase	I:C0164786
B	I:C0164786
(	O
PI3K	O
-	O
AKT	B:C0164786
)	O
is	O
upregulated	O
in	O
multiple	O
myeloma	I:C0026764
(	O
MM	I:C0026764
)	I:C0026764
.	O

Phosphoinositide	O
-	I:C0044602
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
and	O
protein	O
kinase	I:C0164786
B	I:C0164786
(	O
PI3K	O
-	O
AKT	O
)	O
is	O
upregulated	B:C0041904
in	O
multiple	O
myeloma	I:C0026764
(	O
MM	I:C0026764
)	I:C0026764
.	O

Phosphoinositide	O
-	I:C0044602
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
and	O
protein	O
kinase	I:C0164786
B	I:C0164786
(	O
PI3K	O
-	O
AKT	O
)	O
is	O
upregulated	O
in	O
multiple	B:C0026764
myeloma	I:C0026764
(	O
MM	I:C0026764
)	I:C0026764
.	O

Phosphoinositide	O
-	I:C0044602
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
and	O
protein	O
kinase	I:C0164786
B	I:C0164786
(	O
PI3K	O
-	O
AKT	O
)	O
is	O
upregulated	O
in	O
multiple	O
myeloma	I:C0026764
(	B:C0026764
MM	I:C0026764
)	I:C0026764
.	O

Using	O
a	O
combination	O
of	O
short	B:C2930586
hairpin	I:C2930586
RNA	I:C2930586
(	O
shRNA	I:C2930586
)	I:C2930586
lentivirus	O
-	O
mediated	O
knockdown	O
and	O
pharmacologic	O
isoform	I:C0597298
-	I:C0597298
specific	I:C0597298
inhibition	O
we	O
investigated	O
the	O
role	O
of	O
the	O
PI3K	O
p110	I:C2713509
γ	I:C2713509
(	O
PI3	I:C2713509
K	I:C2713509
γ	I:C2713509
)	I:C2713509
subunit	O
in	O
regulating	O
multiple	O
myeloma	I:C0026764
proliferation	O
and	O
bone	O
marrow	I:C0005953
microenvironment	O
-	O
induced	O
multiple	O
myeloma	I:C0026764
interactions	O
.	O

Using	O
a	O
combination	O
of	O
short	O
hairpin	I:C2930586
RNA	I:C2930586
(	B:C2930586
shRNA	I:C2930586
)	I:C2930586
lentivirus	O
-	O
mediated	O
knockdown	O
and	O
pharmacologic	O
isoform	I:C0597298
-	I:C0597298
specific	I:C0597298
inhibition	O
we	O
investigated	O
the	O
role	O
of	O
the	O
PI3K	O
p110	I:C2713509
γ	I:C2713509
(	O
PI3	I:C2713509
K	I:C2713509
γ	I:C2713509
)	I:C2713509
subunit	O
in	O
regulating	O
multiple	O
myeloma	I:C0026764
proliferation	O
and	O
bone	O
marrow	I:C0005953
microenvironment	O
-	O
induced	O
multiple	O
myeloma	I:C0026764
interactions	O
.	O

Using	O
a	O
combination	O
of	O
short	O
hairpin	I:C2930586
RNA	I:C2930586
(	O
shRNA	I:C2930586
)	I:C2930586
lentivirus	B:C0079679
-	O
mediated	O
knockdown	O
and	O
pharmacologic	O
isoform	I:C0597298
-	I:C0597298
specific	I:C0597298
inhibition	O
we	O
investigated	O
the	O
role	O
of	O
the	O
PI3K	O
p110	I:C2713509
γ	I:C2713509
(	O
PI3	I:C2713509
K	I:C2713509
γ	I:C2713509
)	I:C2713509
subunit	O
in	O
regulating	O
multiple	O
myeloma	I:C0026764
proliferation	O
and	O
bone	O
marrow	I:C0005953
microenvironment	O
-	O
induced	O
multiple	O
myeloma	I:C0026764
interactions	O
.	O

Using	O
a	O
combination	O
of	O
short	O
hairpin	I:C2930586
RNA	I:C2930586
(	O
shRNA	I:C2930586
)	I:C2930586
lentivirus	O
-	O
mediated	O
knockdown	B:C2350567
and	O
pharmacologic	O
isoform	I:C0597298
-	I:C0597298
specific	I:C0597298
inhibition	O
we	O
investigated	O
the	O
role	O
of	O
the	O
PI3K	O
p110	I:C2713509
γ	I:C2713509
(	O
PI3	I:C2713509
K	I:C2713509
γ	I:C2713509
)	I:C2713509
subunit	O
in	O
regulating	O
multiple	O
myeloma	I:C0026764
proliferation	O
and	O
bone	O
marrow	I:C0005953
microenvironment	O
-	O
induced	O
multiple	O
myeloma	I:C0026764
interactions	O
.	O

Using	O
a	O
combination	O
of	O
short	O
hairpin	I:C2930586
RNA	I:C2930586
(	O
shRNA	I:C2930586
)	I:C2930586
lentivirus	O
-	O
mediated	O
knockdown	O
and	O
pharmacologic	B:C0597298
isoform	I:C0597298
-	I:C0597298
specific	I:C0597298
inhibition	O
we	O
investigated	O
the	O
role	O
of	O
the	O
PI3K	O
p110	I:C2713509
γ	I:C2713509
(	O
PI3	I:C2713509
K	I:C2713509
γ	I:C2713509
)	I:C2713509
subunit	O
in	O
regulating	O
multiple	O
myeloma	I:C0026764
proliferation	O
and	O
bone	O
marrow	I:C0005953
microenvironment	O
-	O
induced	O
multiple	O
myeloma	I:C0026764
interactions	O
.	O

Using	O
a	O
combination	O
of	O
short	O
hairpin	I:C2930586
RNA	I:C2930586
(	O
shRNA	I:C2930586
)	I:C2930586
lentivirus	O
-	O
mediated	O
knockdown	O
and	O
pharmacologic	O
isoform	I:C0597298
-	I:C0597298
specific	I:C0597298
inhibition	O
we	O
investigated	O
the	O
role	O
of	O
the	O
PI3K	B:C2713509
p110	I:C2713509
γ	I:C2713509
(	O
PI3	I:C2713509
K	I:C2713509
γ	I:C2713509
)	I:C2713509
subunit	O
in	O
regulating	O
multiple	O
myeloma	I:C0026764
proliferation	O
and	O
bone	O
marrow	I:C0005953
microenvironment	O
-	O
induced	O
multiple	O
myeloma	I:C0026764
interactions	O
.	O

Using	O
a	O
combination	O
of	O
short	O
hairpin	I:C2930586
RNA	I:C2930586
(	O
shRNA	I:C2930586
)	I:C2930586
lentivirus	O
-	O
mediated	O
knockdown	O
and	O
pharmacologic	O
isoform	I:C0597298
-	I:C0597298
specific	I:C0597298
inhibition	O
we	O
investigated	O
the	O
role	O
of	O
the	O
PI3K	O
p110	I:C2713509
γ	I:C2713509
(	B:C2713509
PI3	I:C2713509
K	I:C2713509
γ	I:C2713509
)	I:C2713509
subunit	O
in	O
regulating	O
multiple	O
myeloma	I:C0026764
proliferation	O
and	O
bone	O
marrow	I:C0005953
microenvironment	O
-	O
induced	O
multiple	O
myeloma	I:C0026764
interactions	O
.	O

Using	O
a	O
combination	O
of	O
short	O
hairpin	I:C2930586
RNA	I:C2930586
(	O
shRNA	I:C2930586
)	I:C2930586
lentivirus	O
-	O
mediated	O
knockdown	O
and	O
pharmacologic	O
isoform	I:C0597298
-	I:C0597298
specific	I:C0597298
inhibition	O
we	O
investigated	O
the	O
role	O
of	O
the	O
PI3K	O
p110	I:C2713509
γ	I:C2713509
(	O
PI3	I:C2713509
K	I:C2713509
γ	I:C2713509
)	I:C2713509
subunit	B:C0599220
in	O
regulating	O
multiple	O
myeloma	I:C0026764
proliferation	O
and	O
bone	O
marrow	I:C0005953
microenvironment	O
-	O
induced	O
multiple	O
myeloma	I:C0026764
interactions	O
.	O

Using	O
a	O
combination	O
of	O
short	O
hairpin	I:C2930586
RNA	I:C2930586
(	O
shRNA	I:C2930586
)	I:C2930586
lentivirus	O
-	O
mediated	O
knockdown	O
and	O
pharmacologic	O
isoform	I:C0597298
-	I:C0597298
specific	I:C0597298
inhibition	O
we	O
investigated	O
the	O
role	O
of	O
the	O
PI3K	O
p110	I:C2713509
γ	I:C2713509
(	O
PI3	I:C2713509
K	I:C2713509
γ	I:C2713509
)	I:C2713509
subunit	O
in	O
regulating	O
multiple	B:C0026764
myeloma	I:C0026764
proliferation	O
and	O
bone	O
marrow	I:C0005953
microenvironment	O
-	O
induced	O
multiple	O
myeloma	I:C0026764
interactions	O
.	O

Using	O
a	O
combination	O
of	O
short	O
hairpin	I:C2930586
RNA	I:C2930586
(	O
shRNA	I:C2930586
)	I:C2930586
lentivirus	O
-	O
mediated	O
knockdown	O
and	O
pharmacologic	O
isoform	I:C0597298
-	I:C0597298
specific	I:C0597298
inhibition	O
we	O
investigated	O
the	O
role	O
of	O
the	O
PI3K	O
p110	I:C2713509
γ	I:C2713509
(	O
PI3	I:C2713509
K	I:C2713509
γ	I:C2713509
)	I:C2713509
subunit	O
in	O
regulating	O
multiple	O
myeloma	I:C0026764
proliferation	B:C0596290
and	O
bone	O
marrow	I:C0005953
microenvironment	O
-	O
induced	O
multiple	O
myeloma	I:C0026764
interactions	O
.	O

Using	O
a	O
combination	O
of	O
short	O
hairpin	I:C2930586
RNA	I:C2930586
(	O
shRNA	I:C2930586
)	I:C2930586
lentivirus	O
-	O
mediated	O
knockdown	O
and	O
pharmacologic	O
isoform	I:C0597298
-	I:C0597298
specific	I:C0597298
inhibition	O
we	O
investigated	O
the	O
role	O
of	O
the	O
PI3K	O
p110	I:C2713509
γ	I:C2713509
(	O
PI3	I:C2713509
K	I:C2713509
γ	I:C2713509
)	I:C2713509
subunit	O
in	O
regulating	O
multiple	O
myeloma	I:C0026764
proliferation	O
and	O
bone	B:C0005953
marrow	I:C0005953
microenvironment	O
-	O
induced	O
multiple	O
myeloma	I:C0026764
interactions	O
.	O

Using	O
a	O
combination	O
of	O
short	O
hairpin	I:C2930586
RNA	I:C2930586
(	O
shRNA	I:C2930586
)	I:C2930586
lentivirus	O
-	O
mediated	O
knockdown	O
and	O
pharmacologic	O
isoform	I:C0597298
-	I:C0597298
specific	I:C0597298
inhibition	O
we	O
investigated	O
the	O
role	O
of	O
the	O
PI3K	O
p110	I:C2713509
γ	I:C2713509
(	O
PI3	I:C2713509
K	I:C2713509
γ	I:C2713509
)	I:C2713509
subunit	O
in	O
regulating	O
multiple	O
myeloma	I:C0026764
proliferation	O
and	O
bone	O
marrow	I:C0005953
microenvironment	O
-	O
induced	O
multiple	B:C0026764
myeloma	I:C0026764
interactions	O
.	O

We	O
compared	O
this	O
with	O
inhibition	O
of	O
the	O
PI3K	B:C1450115
p110	I:C1450115
δ	I:C1450115
(	O
PI3	I:C1450115
kδ	I:C1450115
)	I:C1450115
subunit	O
and	O
with	O
combined	O
PI3K	O
p110δ	I:C1450115
/	O
γ	O
dual	O
inhibition	O
.	O

We	O
compared	O
this	O
with	O
inhibition	O
of	O
the	O
PI3K	O
p110	I:C1450115
δ	I:C1450115
(	B:C1450115
PI3	I:C1450115
kδ	I:C1450115
)	I:C1450115
subunit	O
and	O
with	O
combined	O
PI3K	O
p110δ	I:C1450115
/	O
γ	O
dual	O
inhibition	O
.	O

We	O
compared	O
this	O
with	O
inhibition	O
of	O
the	O
PI3K	O
p110	I:C1450115
δ	I:C1450115
(	O
PI3	I:C1450115
kδ	I:C1450115
)	I:C1450115
subunit	B:C0599220
and	O
with	O
combined	O
PI3K	O
p110δ	I:C1450115
/	O
γ	O
dual	O
inhibition	O
.	O

We	O
compared	O
this	O
with	O
inhibition	O
of	O
the	O
PI3K	O
p110	I:C1450115
δ	I:C1450115
(	O
PI3	I:C1450115
kδ	I:C1450115
)	I:C1450115
subunit	O
and	O
with	O
combined	O
PI3K	B:C1450115
p110δ	I:C1450115
/	O
γ	O
dual	O
inhibition	O
.	O

We	O
compared	O
this	O
with	O
inhibition	O
of	O
the	O
PI3K	O
p110	I:C1450115
δ	I:C1450115
(	O
PI3	I:C1450115
kδ	I:C1450115
)	I:C1450115
subunit	O
and	O
with	O
combined	O
PI3K	O
p110δ	I:C1450115
/	O
γ	B:C2713509
dual	O
inhibition	O
.	O

We	O
found	O
that	O
multiple	B:C0026764
myeloma	I:C0026764
cell	O
adhesion	I:C0007577
and	O
migration	O
were	O
PI3K	O
p110	I:C2713509
γ	I:C2713509
-	O
specific	O
functions	O
,	O
with	O
PI3K	O
p110	I:C1450115
δ	I:C1450115
inhibition	O
having	O
no	O
effect	O
in	O
multiple	O
myeloma	I:C0026764
adhesion	O
or	O
migration	O
assays	O
.	O

We	O
found	O
that	O
multiple	O
myeloma	I:C0026764
cell	B:C0007577
adhesion	I:C0007577
and	O
migration	O
were	O
PI3K	O
p110	I:C2713509
γ	I:C2713509
-	O
specific	O
functions	O
,	O
with	O
PI3K	O
p110	I:C1450115
δ	I:C1450115
inhibition	O
having	O
no	O
effect	O
in	O
multiple	O
myeloma	I:C0026764
adhesion	O
or	O
migration	O
assays	O
.	O

We	O
found	O
that	O
multiple	O
myeloma	I:C0026764
cell	O
adhesion	I:C0007577
and	O
migration	B:C1622501
were	O
PI3K	O
p110	I:C2713509
γ	I:C2713509
-	O
specific	O
functions	O
,	O
with	O
PI3K	O
p110	I:C1450115
δ	I:C1450115
inhibition	O
having	O
no	O
effect	O
in	O
multiple	O
myeloma	I:C0026764
adhesion	O
or	O
migration	O
assays	O
.	O

We	O
found	O
that	O
multiple	O
myeloma	I:C0026764
cell	O
adhesion	I:C0007577
and	O
migration	O
were	O
PI3K	B:C2713509
p110	I:C2713509
γ	I:C2713509
-	O
specific	O
functions	O
,	O
with	O
PI3K	O
p110	I:C1450115
δ	I:C1450115
inhibition	O
having	O
no	O
effect	O
in	O
multiple	O
myeloma	I:C0026764
adhesion	O
or	O
migration	O
assays	O
.	O

We	O
found	O
that	O
multiple	O
myeloma	I:C0026764
cell	O
adhesion	I:C0007577
and	O
migration	O
were	O
PI3K	O
p110	I:C2713509
γ	I:C2713509
-	O
specific	O
functions	O
,	O
with	O
PI3K	B:C1450115
p110	I:C1450115
δ	I:C1450115
inhibition	O
having	O
no	O
effect	O
in	O
multiple	O
myeloma	I:C0026764
adhesion	O
or	O
migration	O
assays	O
.	O

We	O
found	O
that	O
multiple	O
myeloma	I:C0026764
cell	O
adhesion	I:C0007577
and	O
migration	O
were	O
PI3K	O
p110	I:C2713509
γ	I:C2713509
-	O
specific	O
functions	O
,	O
with	O
PI3K	O
p110	I:C1450115
δ	I:C1450115
inhibition	O
having	O
no	O
effect	O
in	O
multiple	B:C0026764
myeloma	I:C0026764
adhesion	O
or	O
migration	O
assays	O
.	O

We	O
found	O
that	O
multiple	O
myeloma	I:C0026764
cell	O
adhesion	I:C0007577
and	O
migration	O
were	O
PI3K	O
p110	I:C2713509
γ	I:C2713509
-	O
specific	O
functions	O
,	O
with	O
PI3K	O
p110	I:C1450115
δ	I:C1450115
inhibition	O
having	O
no	O
effect	O
in	O
multiple	O
myeloma	I:C0026764
adhesion	B:C0007577
or	O
migration	O
assays	O
.	O

We	O
found	O
that	O
multiple	O
myeloma	I:C0026764
cell	O
adhesion	I:C0007577
and	O
migration	O
were	O
PI3K	O
p110	I:C2713509
γ	I:C2713509
-	O
specific	O
functions	O
,	O
with	O
PI3K	O
p110	I:C1450115
δ	I:C1450115
inhibition	O
having	O
no	O
effect	O
in	O
multiple	O
myeloma	I:C0026764
adhesion	O
or	O
migration	B:C1622501
assays	O
.	O

We	O
found	O
that	O
multiple	O
myeloma	I:C0026764
cell	O
adhesion	I:C0007577
and	O
migration	O
were	O
PI3K	O
p110	I:C2713509
γ	I:C2713509
-	O
specific	O
functions	O
,	O
with	O
PI3K	O
p110	I:C1450115
δ	I:C1450115
inhibition	O
having	O
no	O
effect	O
in	O
multiple	O
myeloma	I:C0026764
adhesion	O
or	O
migration	O
assays	B:C1510438
.	O

At	O
concentration	O
of	O
the	O
dual	O
PI3K	B:C1450115
δ	I:C1450115
/	O
γ	O
inhibitor	O
duvelisib	O
,	O
which	O
can	O
be	O
achieved	O
in	O
vivo	I:C1515655
we	O
saw	O
a	O
decrease	O
in	O
AKT	O
phosphorylation	O
at	O
s473	O
after	O
tumour	O
activation	O
by	O
bone	O
marrow	I:C1640380
stromal	I:C1640380
cells	I:C1640380
(	O
BMSC	I:C1640380
)	I:C1640380
and	O
interleukin	O
-	I:C0021760
6	I:C0021760
.	O

At	O
concentration	O
of	O
the	O
dual	O
PI3K	O
δ	I:C1450115
/	O
γ	B:C2713509
inhibitor	O
duvelisib	O
,	O
which	O
can	O
be	O
achieved	O
in	O
vivo	I:C1515655
we	O
saw	O
a	O
decrease	O
in	O
AKT	O
phosphorylation	O
at	O
s473	O
after	O
tumour	O
activation	O
by	O
bone	O
marrow	I:C1640380
stromal	I:C1640380
cells	I:C1640380
(	O
BMSC	I:C1640380
)	I:C1640380
and	O
interleukin	O
-	I:C0021760
6	I:C0021760
.	O

At	O
concentration	O
of	O
the	O
dual	O
PI3K	O
δ	I:C1450115
/	O
γ	O
inhibitor	O
duvelisib	B:C4079854
,	O
which	O
can	O
be	O
achieved	O
in	O
vivo	I:C1515655
we	O
saw	O
a	O
decrease	O
in	O
AKT	O
phosphorylation	O
at	O
s473	O
after	O
tumour	O
activation	O
by	O
bone	O
marrow	I:C1640380
stromal	I:C1640380
cells	I:C1640380
(	O
BMSC	I:C1640380
)	I:C1640380
and	O
interleukin	O
-	I:C0021760
6	I:C0021760
.	O

At	O
concentration	O
of	O
the	O
dual	O
PI3K	O
δ	I:C1450115
/	O
γ	O
inhibitor	O
duvelisib	O
,	O
which	O
can	O
be	O
achieved	O
in	B:C1515655
vivo	I:C1515655
we	O
saw	O
a	O
decrease	O
in	O
AKT	O
phosphorylation	O
at	O
s473	O
after	O
tumour	O
activation	O
by	O
bone	O
marrow	I:C1640380
stromal	I:C1640380
cells	I:C1640380
(	O
BMSC	I:C1640380
)	I:C1640380
and	O
interleukin	O
-	I:C0021760
6	I:C0021760
.	O

At	O
concentration	O
of	O
the	O
dual	O
PI3K	O
δ	I:C1450115
/	O
γ	O
inhibitor	O
duvelisib	O
,	O
which	O
can	O
be	O
achieved	O
in	O
vivo	I:C1515655
we	O
saw	O
a	O
decrease	O
in	O
AKT	B:C0164786
phosphorylation	O
at	O
s473	O
after	O
tumour	O
activation	O
by	O
bone	O
marrow	I:C1640380
stromal	I:C1640380
cells	I:C1640380
(	O
BMSC	I:C1640380
)	I:C1640380
and	O
interleukin	O
-	I:C0021760
6	I:C0021760
.	O

At	O
concentration	O
of	O
the	O
dual	O
PI3K	O
δ	I:C1450115
/	O
γ	O
inhibitor	O
duvelisib	O
,	O
which	O
can	O
be	O
achieved	O
in	O
vivo	I:C1515655
we	O
saw	O
a	O
decrease	O
in	O
AKT	O
phosphorylation	B:C0031715
at	O
s473	O
after	O
tumour	O
activation	O
by	O
bone	O
marrow	I:C1640380
stromal	I:C1640380
cells	I:C1640380
(	O
BMSC	I:C1640380
)	I:C1640380
and	O
interleukin	O
-	I:C0021760
6	I:C0021760
.	O

At	O
concentration	O
of	O
the	O
dual	O
PI3K	O
δ	I:C1450115
/	O
γ	O
inhibitor	O
duvelisib	O
,	O
which	O
can	O
be	O
achieved	O
in	O
vivo	I:C1515655
we	O
saw	O
a	O
decrease	O
in	O
AKT	O
phosphorylation	O
at	O
s473	B:C1519254
after	O
tumour	O
activation	O
by	O
bone	O
marrow	I:C1640380
stromal	I:C1640380
cells	I:C1640380
(	O
BMSC	I:C1640380
)	I:C1640380
and	O
interleukin	O
-	I:C0021760
6	I:C0021760
.	O

At	O
concentration	O
of	O
the	O
dual	O
PI3K	O
δ	I:C1450115
/	O
γ	O
inhibitor	O
duvelisib	O
,	O
which	O
can	O
be	O
achieved	O
in	O
vivo	I:C1515655
we	O
saw	O
a	O
decrease	O
in	O
AKT	O
phosphorylation	O
at	O
s473	O
after	O
tumour	B:C0027651
activation	O
by	O
bone	O
marrow	I:C1640380
stromal	I:C1640380
cells	I:C1640380
(	O
BMSC	I:C1640380
)	I:C1640380
and	O
interleukin	O
-	I:C0021760
6	I:C0021760
.	O

At	O
concentration	O
of	O
the	O
dual	O
PI3K	O
δ	I:C1450115
/	O
γ	O
inhibitor	O
duvelisib	O
,	O
which	O
can	O
be	O
achieved	O
in	O
vivo	I:C1515655
we	O
saw	O
a	O
decrease	O
in	O
AKT	O
phosphorylation	O
at	O
s473	O
after	O
tumour	O
activation	O
by	O
bone	B:C1640380
marrow	I:C1640380
stromal	I:C1640380
cells	I:C1640380
(	O
BMSC	I:C1640380
)	I:C1640380
and	O
interleukin	O
-	I:C0021760
6	I:C0021760
.	O

At	O
concentration	O
of	O
the	O
dual	O
PI3K	O
δ	I:C1450115
/	O
γ	O
inhibitor	O
duvelisib	O
,	O
which	O
can	O
be	O
achieved	O
in	O
vivo	I:C1515655
we	O
saw	O
a	O
decrease	O
in	O
AKT	O
phosphorylation	O
at	O
s473	O
after	O
tumour	O
activation	O
by	O
bone	O
marrow	I:C1640380
stromal	I:C1640380
cells	I:C1640380
(	B:C1640380
BMSC	I:C1640380
)	I:C1640380
and	O
interleukin	O
-	I:C0021760
6	I:C0021760
.	O

At	O
concentration	O
of	O
the	O
dual	O
PI3K	O
δ	I:C1450115
/	O
γ	O
inhibitor	O
duvelisib	O
,	O
which	O
can	O
be	O
achieved	O
in	O
vivo	I:C1515655
we	O
saw	O
a	O
decrease	O
in	O
AKT	O
phosphorylation	O
at	O
s473	O
after	O
tumour	O
activation	O
by	O
bone	O
marrow	I:C1640380
stromal	I:C1640380
cells	I:C1640380
(	O
BMSC	I:C1640380
)	I:C1640380
and	O
interleukin	B:C0021760
-	I:C0021760
6	I:C0021760
.	O

Moreover	O
,	O
after	O
drug	B:C0013216
treatment	I:C0013216
of	O
bone	O
marrow	I:C1640380
stromal	I:C1640380
cells	I:C1640380
/	O
tumour	O
co-culture	O
activation	O
assays	O
only	O
dual	O
PI3K	O
p110δ	I:C1450115
/	O
γ	O
inhibition	O
was	O
able	O
to	O
induce	O
multiple	O
myeloma	I:C0026764
apoptosis	O
.	O

Moreover	O
,	O
after	O
drug	O
treatment	I:C0013216
of	O
bone	B:C1640380
marrow	I:C1640380
stromal	I:C1640380
cells	I:C1640380
/	O
tumour	O
co-culture	O
activation	O
assays	O
only	O
dual	O
PI3K	O
p110δ	I:C1450115
/	O
γ	O
inhibition	O
was	O
able	O
to	O
induce	O
multiple	O
myeloma	I:C0026764
apoptosis	O
.	O

Moreover	O
,	O
after	O
drug	O
treatment	I:C0013216
of	O
bone	O
marrow	I:C1640380
stromal	I:C1640380
cells	I:C1640380
/	O
tumour	B:C0027651
co-culture	O
activation	O
assays	O
only	O
dual	O
PI3K	O
p110δ	I:C1450115
/	O
γ	O
inhibition	O
was	O
able	O
to	O
induce	O
multiple	O
myeloma	I:C0026764
apoptosis	O
.	O

Moreover	O
,	O
after	O
drug	O
treatment	I:C0013216
of	O
bone	O
marrow	I:C1640380
stromal	I:C1640380
cells	I:C1640380
/	O
tumour	O
co-culture	B:C0430400
activation	O
assays	O
only	O
dual	O
PI3K	O
p110δ	I:C1450115
/	O
γ	O
inhibition	O
was	O
able	O
to	O
induce	O
multiple	O
myeloma	I:C0026764
apoptosis	O
.	O

Moreover	O
,	O
after	O
drug	O
treatment	I:C0013216
of	O
bone	O
marrow	I:C1640380
stromal	I:C1640380
cells	I:C1640380
/	O
tumour	O
co-culture	O
activation	O
assays	B:C1510438
only	O
dual	O
PI3K	O
p110δ	I:C1450115
/	O
γ	O
inhibition	O
was	O
able	O
to	O
induce	O
multiple	O
myeloma	I:C0026764
apoptosis	O
.	O

Moreover	O
,	O
after	O
drug	O
treatment	I:C0013216
of	O
bone	O
marrow	I:C1640380
stromal	I:C1640380
cells	I:C1640380
/	O
tumour	O
co-culture	O
activation	O
assays	O
only	O
dual	O
PI3K	B:C1450115
p110δ	I:C1450115
/	O
γ	O
inhibition	O
was	O
able	O
to	O
induce	O
multiple	O
myeloma	I:C0026764
apoptosis	O
.	O

Moreover	O
,	O
after	O
drug	O
treatment	I:C0013216
of	O
bone	O
marrow	I:C1640380
stromal	I:C1640380
cells	I:C1640380
/	O
tumour	O
co-culture	O
activation	O
assays	O
only	O
dual	O
PI3K	O
p110δ	I:C1450115
/	O
γ	B:C2713509
inhibition	O
was	O
able	O
to	O
induce	O
multiple	O
myeloma	I:C0026764
apoptosis	O
.	O

Moreover	O
,	O
after	O
drug	O
treatment	I:C0013216
of	O
bone	O
marrow	I:C1640380
stromal	I:C1640380
cells	I:C1640380
/	O
tumour	O
co-culture	O
activation	O
assays	O
only	O
dual	O
PI3K	O
p110δ	I:C1450115
/	O
γ	O
inhibition	O
was	O
able	O
to	O
induce	O
multiple	B:C0026764
myeloma	I:C0026764
apoptosis	O
.	O

Moreover	O
,	O
after	O
drug	O
treatment	I:C0013216
of	O
bone	O
marrow	I:C1640380
stromal	I:C1640380
cells	I:C1640380
/	O
tumour	O
co-culture	O
activation	O
assays	O
only	O
dual	O
PI3K	O
p110δ	I:C1450115
/	O
γ	O
inhibition	O
was	O
able	O
to	O
induce	O
multiple	O
myeloma	I:C0026764
apoptosis	B:C0162638
.	O

short	B:C2930586
hairpin	I:C2930586
RNA	I:C2930586
lentiviral	O
-	O
mediated	O
targeting	O
of	O
either	O
PI3K	O
δ	I:C1450115
or	O
PI3K	O
p110	I:C2713509
γ	I:C2713509
alone	O
,	O
or	O
both	O
in	O
combination	O
,	O
increased	O
survival	O
of	O
NSG	O
mice	I:C0025929
xeno	O
-	I:C0522537
transplanted	I:C0522537
with	O
multiple	O
myeloma	I:C0026764
cells	O
.	O

short	O
hairpin	I:C2930586
RNA	I:C2930586
lentiviral	B:C0079679
-	O
mediated	O
targeting	O
of	O
either	O
PI3K	O
δ	I:C1450115
or	O
PI3K	O
p110	I:C2713509
γ	I:C2713509
alone	O
,	O
or	O
both	O
in	O
combination	O
,	O
increased	O
survival	O
of	O
NSG	O
mice	I:C0025929
xeno	O
-	I:C0522537
transplanted	I:C0522537
with	O
multiple	O
myeloma	I:C0026764
cells	O
.	O

short	O
hairpin	I:C2930586
RNA	I:C2930586
lentiviral	O
-	O
mediated	O
targeting	O
of	O
either	O
PI3K	B:C1450115
δ	I:C1450115
or	O
PI3K	O
p110	I:C2713509
γ	I:C2713509
alone	O
,	O
or	O
both	O
in	O
combination	O
,	O
increased	O
survival	O
of	O
NSG	O
mice	I:C0025929
xeno	O
-	I:C0522537
transplanted	I:C0522537
with	O
multiple	O
myeloma	I:C0026764
cells	O
.	O

short	O
hairpin	I:C2930586
RNA	I:C2930586
lentiviral	O
-	O
mediated	O
targeting	O
of	O
either	O
PI3K	O
δ	I:C1450115
or	O
PI3K	B:C2713509
p110	I:C2713509
γ	I:C2713509
alone	O
,	O
or	O
both	O
in	O
combination	O
,	O
increased	O
survival	O
of	O
NSG	O
mice	I:C0025929
xeno	O
-	I:C0522537
transplanted	I:C0522537
with	O
multiple	O
myeloma	I:C0026764
cells	O
.	O

short	O
hairpin	I:C2930586
RNA	I:C2930586
lentiviral	O
-	O
mediated	O
targeting	O
of	O
either	O
PI3K	O
δ	I:C1450115
or	O
PI3K	O
p110	I:C2713509
γ	I:C2713509
alone	O
,	O
or	O
both	O
in	O
combination	O
,	O
increased	O
survival	O
of	O
NSG	B:C0025929
mice	I:C0025929
xeno	O
-	I:C0522537
transplanted	I:C0522537
with	O
multiple	O
myeloma	I:C0026764
cells	O
.	O

short	O
hairpin	I:C2930586
RNA	I:C2930586
lentiviral	O
-	O
mediated	O
targeting	O
of	O
either	O
PI3K	O
δ	I:C1450115
or	O
PI3K	O
p110	I:C2713509
γ	I:C2713509
alone	O
,	O
or	O
both	O
in	O
combination	O
,	O
increased	O
survival	O
of	O
NSG	O
mice	I:C0025929
xeno	B:C0522537
-	I:C0522537
transplanted	I:C0522537
with	O
multiple	O
myeloma	I:C0026764
cells	O
.	O

short	O
hairpin	I:C2930586
RNA	I:C2930586
lentiviral	O
-	O
mediated	O
targeting	O
of	O
either	O
PI3K	O
δ	I:C1450115
or	O
PI3K	O
p110	I:C2713509
γ	I:C2713509
alone	O
,	O
or	O
both	O
in	O
combination	O
,	O
increased	O
survival	O
of	O
NSG	O
mice	I:C0025929
xeno	O
-	I:C0522537
transplanted	I:C0522537
with	O
multiple	B:C0026764
myeloma	I:C0026764
cells	O
.	O

short	O
hairpin	I:C2930586
RNA	I:C2930586
lentiviral	O
-	O
mediated	O
targeting	O
of	O
either	O
PI3K	O
δ	I:C1450115
or	O
PI3K	O
p110	I:C2713509
γ	I:C2713509
alone	O
,	O
or	O
both	O
in	O
combination	O
,	O
increased	O
survival	O
of	O
NSG	O
mice	I:C0025929
xeno	O
-	I:C0522537
transplanted	I:C0522537
with	O
multiple	O
myeloma	I:C0026764
cells	B:C0007634
.	O

Moreover	O
,	O
treatment	O
with	O
duvelisib	B:C4079854
reduced	O
multiple	O
myeloma	I:C0026764
tumour	O
burden	O
in	O
vivo	I:C1515655
.	O

Moreover	O
,	O
treatment	O
with	O
duvelisib	O
reduced	O
multiple	B:C0026764
myeloma	I:C0026764
tumour	O
burden	O
in	O
vivo	I:C1515655
.	O

Moreover	O
,	O
treatment	O
with	O
duvelisib	O
reduced	O
multiple	O
myeloma	I:C0026764
tumour	B:C0027651
burden	O
in	O
vivo	I:C1515655
.	O

Moreover	O
,	O
treatment	O
with	O
duvelisib	O
reduced	O
multiple	O
myeloma	I:C0026764
tumour	O
burden	O
in	B:C1515655
vivo	I:C1515655
.	O

We	O
report	B:C0684224
that	O
PI3K	O
δ	I:C1450115
and	O
PI3K	O
γ	I:C2713509
isoforms	I:C2713509
have	O
distinct	O
functions	O
in	O
multiple	O
myeloma	I:C0026764
and	O
that	O
combined	O
PI3K	O
p110δ	I:C1450115
/	O
γ	O
isoform	O
inhibition	O
has	O
anti	O
-	O
multiple	O
myeloma	I:C0026764
activity	O
.	O

We	O
report	O
that	O
PI3K	B:C1450115
δ	I:C1450115
and	O
PI3K	O
γ	I:C2713509
isoforms	I:C2713509
have	O
distinct	O
functions	O
in	O
multiple	O
myeloma	I:C0026764
and	O
that	O
combined	O
PI3K	O
p110δ	I:C1450115
/	O
γ	O
isoform	O
inhibition	O
has	O
anti	O
-	O
multiple	O
myeloma	I:C0026764
activity	O
.	O

We	O
report	O
that	O
PI3K	O
δ	I:C1450115
and	O
PI3K	B:C2713509
γ	I:C2713509
isoforms	I:C2713509
have	O
distinct	O
functions	O
in	O
multiple	O
myeloma	I:C0026764
and	O
that	O
combined	O
PI3K	O
p110δ	I:C1450115
/	O
γ	O
isoform	O
inhibition	O
has	O
anti	O
-	O
multiple	O
myeloma	I:C0026764
activity	O
.	O

We	O
report	O
that	O
PI3K	O
δ	I:C1450115
and	O
PI3K	O
γ	I:C2713509
isoforms	I:C2713509
have	O
distinct	O
functions	O
in	O
multiple	B:C0026764
myeloma	I:C0026764
and	O
that	O
combined	O
PI3K	O
p110δ	I:C1450115
/	O
γ	O
isoform	O
inhibition	O
has	O
anti	O
-	O
multiple	O
myeloma	I:C0026764
activity	O
.	O

We	O
report	O
that	O
PI3K	O
δ	I:C1450115
and	O
PI3K	O
γ	I:C2713509
isoforms	I:C2713509
have	O
distinct	O
functions	O
in	O
multiple	O
myeloma	I:C0026764
and	O
that	O
combined	O
PI3K	B:C1450115
p110δ	I:C1450115
/	O
γ	O
isoform	O
inhibition	O
has	O
anti	O
-	O
multiple	O
myeloma	I:C0026764
activity	O
.	O

We	O
report	O
that	O
PI3K	O
δ	I:C1450115
and	O
PI3K	O
γ	I:C2713509
isoforms	I:C2713509
have	O
distinct	O
functions	O
in	O
multiple	O
myeloma	I:C0026764
and	O
that	O
combined	O
PI3K	O
p110δ	I:C1450115
/	O
γ	B:C2713509
isoform	O
inhibition	O
has	O
anti	O
-	O
multiple	O
myeloma	I:C0026764
activity	O
.	O

We	O
report	O
that	O
PI3K	O
δ	I:C1450115
and	O
PI3K	O
γ	I:C2713509
isoforms	I:C2713509
have	O
distinct	O
functions	O
in	O
multiple	O
myeloma	I:C0026764
and	O
that	O
combined	O
PI3K	O
p110δ	I:C1450115
/	O
γ	O
isoform	B:C0597298
inhibition	O
has	O
anti	O
-	O
multiple	O
myeloma	I:C0026764
activity	O
.	O

We	O
report	O
that	O
PI3K	O
δ	I:C1450115
and	O
PI3K	O
γ	I:C2713509
isoforms	I:C2713509
have	O
distinct	O
functions	O
in	O
multiple	O
myeloma	I:C0026764
and	O
that	O
combined	O
PI3K	O
p110δ	I:C1450115
/	O
γ	O
isoform	O
inhibition	O
has	O
anti	O
-	O
multiple	B:C0026764
myeloma	I:C0026764
activity	O
.	O

Here	O
we	O
provide	O
a	O
scientific	B:C0282574
rationale	I:C0282574
for	O
trials	O
of	O
dual	O
PI3K	O
p110δ	I:C1450115
/	O
γ	O
inhibition	O
in	O
patients	O
with	O
multiple	O
myeloma	I:C0026764
.	O

Here	O
we	O
provide	O
a	O
scientific	O
rationale	I:C0282574
for	O
trials	O
of	O
dual	O
PI3K	B:C1450115
p110δ	I:C1450115
/	O
γ	O
inhibition	O
in	O
patients	O
with	O
multiple	O
myeloma	I:C0026764
.	O

Here	O
we	O
provide	O
a	O
scientific	O
rationale	I:C0282574
for	O
trials	O
of	O
dual	O
PI3K	O
p110δ	I:C1450115
/	O
γ	B:C2713509
inhibition	O
in	O
patients	O
with	O
multiple	O
myeloma	I:C0026764
.	O

Here	O
we	O
provide	O
a	O
scientific	O
rationale	I:C0282574
for	O
trials	O
of	O
dual	O
PI3K	O
p110δ	I:C1450115
/	O
γ	O
inhibition	O
in	O
patients	O
with	O
multiple	B:C0026764
myeloma	I:C0026764
.	O

